Making the latest scientific advances in
longevity accessible and achievable for all

Title

NOVOS is the pioneer in consumer longevity, introducing the first formula to 

Address ageing by targeting the 12 fundamental causes of aging. Evidence continues 

to accumulate, demonstrating the efficacy of our industry-leading approach.

Real-World Results

Everyday people achieving extraordinary results with NOVOS and being recognised in

global competitions, by the press, and by their communities and loved ones.

Customer Success Stories

Title

FORTUNE Well

“This 55-year-old single mom makes less than $100k per year and is reverse aging without spending millions.”

BUSINESS INSIDER

“A woman spending around $108 a month on health expenses is beating out a millionaire who spends $2 million per year in anti-aging“

FORTUNE

“This 64-year-old was surprised she ranked 5 in a millionaire’s longevity contest. Here’s her inexpensive routine for a long life“

Created by the Greatest Minds in Longevity

Title

NOVOS’ Scientific and Medical advisory teams are composed of world-renowned, 

leading thinkers from institutions like Harvard Medical School, MIT, the Salk Institute, 

National University of Singapore, and more.

Dr. George Church, PhD 

Harvard Medical School & MIT Professor

“100 most influential people: ‘His contribution to genetic research and the imagination he brings to its application may change the entire world and our experience of life itself.’ ”

Also featured in:

Dr. George Church published the first direct genomic sequencing method in 1984 and is known as the “father” of synthetic biology and personalized genomics. Dr. Church has received various accolades, which include election to the National Academy of Sciences and the National Academy of Engineering. He is a recipient of the American Society for Microbiology Promega Biotechnology Research Award. His most cited work has been published in peer reviewed scientific journals including PNAS, Nature Genetics, Nature Biotechnology, Science, the Journal of Molecular Biology, Nature, and many others.

Dr. Pamela Maher, PhD

University of British Columbia, Salk Institute for Biological Studies

“Maher was one of the first to take aging into account for drug discovery in Alzheimer’s. She identified a class of compounds known as geroneuroprotectors, which slow the aging process in mice.” 

Dr. Maher worked for 5 years as an assistant professor at the Whittier Institute for Diabetes and Endocrinology in La Jolla, CA, then moved to The Scripps Research Institute in 1994 as an associate professor. In 2004, she moved to her current position at The Salk Institute. Her research interests focus on using natural products such as flavonoids, small molecules that are widely distributed in fruits and vegetables, to maintain nerve cell function in the presence of toxic insults, especially in relation to Alzheimer’s, dementia & Parkinson’s.

Dr. J Pedro de Magalhaes, PhD

Harvard Medical School, University of Birmingham

“I think that having the genome sequence of the bowhead whale will allow researchers to study basic molecular processes and identify maintenance mechanisms that help preserve life, avoid entropy and repair molecular damage.”

Dr. de Magalhaes leads the Integrative Genomics of Aging Group at the Institute of Integrative Biology, University of Liverpool, UK. Dr. de Magalhaes completed his postdoc with genomics pioneer, Dr. George Church, at Harvard Medical School. He developed high-throughput approaches for studying aging, including computational tools and databases, statistical models of mortality, and comparative genomics methods for investigating the evolution of longevity. Dr. de Magalhaes maintains several databases related to the impact that drugs & natural substances have on aging.

We've got you covered

Go beyond the longevity solutions and get an insider view of the latest breakthrough science. NOVOS is a Public Benefit Corporation that provides science-based tips, actionable guidance, and expert-backed tools to the public for free.
Thanks for contacting us. We'll get back to you as soon as possible.

NAME

EMAIL

MESSAGE